Novel therapies for patients with chronic myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 271-282

  Giles, Francis J ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Decitabine; FLT3; Histone deacetylase inhibitors; Imatinib; mTOR; Troxacitabine; VEGF

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; AZACITIDINE; BCR ABL PROTEIN; BEVACIZUMAB; CYTARABINE; DEOXYCYTIDINE KINASE; DEPSIPEPTIDE; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; LAMIVUDINE; MIDOSTAURIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PHTHALAZINE DERIVATIVE; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA METHYLATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG USE; FEVER; HUMAN; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SURVIVAL TIME;

EID: 1842689563     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.271     Document Type: Review

References (177)

1. Cortes J, Talpaz M, O'Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98, 1105-1113 (2003).
2. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin. Hematol. 40, 79-86 (2003).
3. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon-α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
4. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
5. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
6. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a Phase 2 study. Blood 99, 1928-1937 (2002).
7. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101, 473-475 (2003).
8. Cortes J, Giles F, O'Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 102, 83-86 (2003).
9. Cortes J, O'Brien S, Talpaz M et al. Clinical significance of molecular response in chronic myeloid leukemia after imatinib (Gleevec) therapy: Low levels of residual disease predict for response duration. Blood (2004) (In Press).
10. Cortes J, Talpaz M, O'Brien S et al. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood 100 95a (2002) (Abstract 350).
11. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann. Intern. Med. 134, 573-586 (2001).
12. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 11, S7-S11 (1997).
13. Nguyen TT, Mohrbacher AF, Tsai YC et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications. Blood 95, 2990-2992 (2000).
14. Asimakopoulos FA, Shteper PJ, Krichevsky S et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94, 2452-2460 (1999).
15. Issa JP, Kantarjian H, Mohan A et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance. Blood 93, 2075-2080 (1999).
16. Zion M, Ben-Yehuda D, Avraham A et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl Acad. Sci. USA 91, 10722-10726 (1994).
17. Ge XQ, Tanaka K, Mansyur A et al. Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region. Cancer Genet. Cytogenet. 126, 102-110 (2001).
18. Roman-Gomez J, Castillejo JA, Jimenez A et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon-α. J. Clin. Oncol. 21, 1472-1479 (2003).
19. Kantarjian HM, O'Brien S, Cortes J et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98, 522-528 (2003).
20. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter Phase II study in elderly patients. J. Clin. Oncol. 18, 956-962 (2000).
21. Kornblith AB, Herndon JE II, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: A Cancer and Leukemia Group B study. J. Clin. Oncol. 20, 2441-2452 (2002).
22. Issa JP, Garcia-Manero G, Mannari R et al. Minimal effective dose of hypomethylating agent decitabine in hematopoietic malignancies. Blood 98, 594a (2001).
23. La Rosee P, Johnson K, Moseson EM et al. Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents. Blood 98, 839a (2001).
24. Nimmanapalli R, Fuino L, Bali P et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63, 5126-5135 (2003).
25. Nimmanapalli R, Fuino L, Stobaugh C et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236-3239 (2003).
26. Thiagalingam S, Cheng KH, Lee HJ et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84-100 (2003).
27. Yu C, Rahmani M, Almenara J et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63, 2118-2126 (2003).
28. Aron JL, Parthun MR, Marcucci G et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and downregulation of c-FLIP protein. Blood 20, 20 (2003).
29. Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94, 3717-3721 (1999).
30. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96, 2240-2245 (2000).
31. Aguayo A, O'Brien S, Keating M et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 96, 768-770 (2000).
32. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin. Oncol. 28, 551-559 (2001).
33. Bellamy WT, Richter L, Sirjani D et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97, 1427-1434 (2001).
34. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761-8766 (1997).
35. Brunner B, Gunsilius E, Schumacher P et al. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J. Hematother. Stem Cell Res. 11, 119-125 (2002).
36. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. 26, 561-569 (2000).
37. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101, 1692-1697 (2003).
38. Fiedler W, Graeven U, Ergun S et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89, 1870-1875 (1997).
39. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996).
40. Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
41. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies. Oncologist 6(Suppl. 5), 32-39 (2001).
42. Giles FJ, Cooper MA, Silverman L et al. Phase II study of SU5416, a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor, in patients with refractory myeloproliferative diseases. Cancer 97, 1920-1928 (2003).
43. Giles FJ, Stopeck AT, Silverman LR et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102, 795-801 (2003).
44. Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15, 29-41 (2000).
45. Mendel DB, Schreck RE, West DC et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 6, 4848-4858 (2000).
46. Pruneri G, Bertolini F, Soligo D et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer 81, 1398-1401 (1999).
47. Saishin Y, Takahashi K, Seo MS et al. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest. Ophthalmol. Vis. Sci. 44, 3656-3662 (2003).
48. Spiekermann K, Faber F, Voswinckel R et al. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp. Hematol. 30, 767-773 (2002).
49. Sukbuntherng J, Cropp G, Hannah A et al. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J. Pharm. Pharmacol. 53, 1629-1636 (2001).
50. Thomas AL, Morgan B, Drevs J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 30, 32-38 (2003).
51. Vajkoczy P, Menger MD, Vollmar B et al. Inhibition of tumor growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1, 31-41 (1999).
52. Verstovsek S, Kantarjian H, Manshouri T et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99, 2265-2267 (2002).
53. Verstovsek S, Estey E, Manshouri T et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 118, 151-156 (2002).
54. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49, 568-581 (2001).
55. Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150, 815-821 (1997).
56. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996).
57. Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
58. Verstovsek S, Kantarjian H, Manshouri T et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99, 2265-2267 (2002).
59. Fong TA, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res. 59, 99-106 (1999).
60. Smolich BD, Yuen HA, West KA et al. The anti-angiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97, 1413-1421 (2001).
61. Yee KW, O'Farrell AM, Smolich BD et al. SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase. Blood 100, 2941-2949 (2002).
62. Spiekermann Y, Bagrintseva K, Schoch C et al. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 100, 3423-3425 (2002).
63. Fenski R, Flesch K, Serve S et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 108, 322-330 (2000).
64. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14, 1766-1776 (2000).
65. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752-1759 (2001).
66. Giles FJ, Cortes JE, Baker SD et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J. Clin. Oncol. 19, 762-771 (2001).
67. Grove KL, Guo X, Liu SH et al. Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 55, 3008-3011 (1995).
68. Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound β-L-(-)- dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 56, 4187-4191 (1996).
69. Giles FJ, Garcia-Manero G, Cortes JE et al. Phase II Study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J. Clin. Oncol. 20, 656-664 (2002).
70. Giles FJ, Faderl S, Thomas DA et al. Randomized Phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol. 21, 1050-1056 (2003).
71. Giles FJ, Feldman EJ, Roboz GJ et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk. Res. 27, 1091-1096 (2003).
72. O'Brien S, Kantarjian H, Keating M et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86, 3322-3326 (1995).
73. O'Brien S, Kantarjian H, Koller C et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93, 4149-4153 (1999).
74. Visani G, Russo D, Ottaviani E et al. Effects of homoharringtonine alone and in combination with α-interferon and cytosine arabinoside on in vitro growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11, 624-628 (1997).
75. Hitt E. Homoharringtonine effective in CML patients. Lancet Oncol. 3, 259 (2002).
76. Kantarjian HM, Talpaz M, Smith TL et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J. Clin. Oncol. 18, 3513-3521 (2000).
77. O'Brien S, Giles F, Talpaz M et al. Results of triple therapy with interferon-α, cytarabine and homoharringtonine and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98, 888-893 (2003).
78. Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164-172 (1999).
79. Ayllon V, Rebollo A. Ras-induced cellular events. Mol. Membr. Biol. 17, 65-73 (2000).
80. Beaupre DM, Kurzrock R. RAS and leukemia: From basic mechanisms to gene-directed therapy. J. Clin. Oncol. 17, 1071-1079 (1999).
81. Kurzrock R, Sebti SM, Kantarjian HM et al. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood 98, 623a (2001) (Abstract 2609).
82. Kurzrock R, Kantarjian HM, Cortes JE et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase I setting. Blood 102, 4527-4534 (2003).
83. Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 17, 1482-1498 (2003).
84. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A Phase I clinical-laboratory correlative trial. Blood 97, 3361-3369 (2001).
85. Karp JE, Kaufmann SH, Adjei AA et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 13, 470-476 (2001).
86. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin. Hematol. 38, 16-23 (2001).
87. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
88. Kurzrock R, Sebti SM, Kantarjian HM et al. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood 98, 623a (2001).
89. Kurzrock R, Cortes JE, Ryback ME et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood 98, 848a (2001).
90. Peters DG, Hoover RR, Gerlach MJ et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97, 1404-1412 (2001).
91. Reichert A, Heisterkamp, N, Daley GQ et al. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97, 1399-4403 (2001).
92. Hoover RR, Mahon F-X, Melo JV et al. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood 98, 617a (2001).
93. Cortes J, Daley GQ, Talpaz M et al. Pilot study of SCH66336 (lonafarnib), a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib. Blood 100, 164a (2002).
94. 3) in the treatment of patients with acute promyelocytic leukemia. Cancer 97, 2218-2224 (2003).
95. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19, 3852-3860 (2001).
96. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Co-operative Research and Development Studies. Oncologist 6(Suppl. 2), 22-28 (2001).
97. Munshi NC, Tricot G, Desikan R et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16, 1835-1837 (2002).
98. Rousselot P, Labaume S, Marolleau JP et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 59, 1041-1048 (1999).
99. Perkins C, Kim CN, Fang G et al. Arsenic induces apoptosis of multi-drug resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95, 1014-1022 (2000).
100. Puccetti E, Guller S, Orleth A et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 60, 3409-3413 (2000).
101. 3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 15, 772-778 (2001).
102. La Rosee P, Johnson K, O'Dwyer ME et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp. Hematol. 30, 729-737 (2002).
103. Mauro MJ, Deininger MW, O'Dwyer ME et al. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase. Blood 100, 781a (2002) (Abstract 3090).
104. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21 (1994).
105. Elliott PJ, Ross JS. The proteasome: A new target for novel drug therapies. Am. J. Clin. Pathol. 116, 637-646 (2001).
106. Kumatori A, Tanaka K, Inamura N et al. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl Acad. Sci. USA 87, 7071-7075 (1990).
107. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
108. Rothwarf DM, Karin M. The NF-κB activation pathway: A paradigm in information transfer from membrane to nucleus. Sci. STKE RE1 (1999).
109. Alkalay I, Yaron A, Hatzubai A et al. Stimulation-dependent IκB α phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 92, 10599-10603 (1995).
110. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-κB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-κB). Oncogene 15, 2267-2275 (1997).
111. Reuther JY, Reuther GW, Cortez D et al. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 12, 968-981 (1998).
112. Korus M, Mahon GM, Cheng L et al. p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr. Oncogene 21, 4601-4612 (2002).
113. Dou QP, McGuire TF, Peng Y et al. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J. Pharmacol. Exp. Ther. 289, 781-790 (1999).
114. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
115. Gatto SR, Scappini B, Verstovsek S et al. In vitro effects of PS-341 alone and in combination with STI571 in BCR-ABL positive cell lines both sensitive and resistant to STI571. Blood 98, 101a (2001).
116. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncog. 4, 595-613 (1993).
117. Rappold I, Ziegler BL, Kohler I et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90, 111-125 (1997).
118. Zeigler FC, Bennett BD, Jordan CT et al. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 84, 2422-2430 (1994).
119. Ebihara Y, Tsuji K, Lyman SD et al. Synergistic action of Flt3 and gp130 signaling in human hematopoiesis. Blood 90, 4363-4368 (1997).
120. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91, 1101-1134 (1998).
121. Yokota S, Kiyoi H, Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11, 1605-1609 (1997).
122. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk. Lymphoma 44, 905-913 (2003).
123. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100, 59-66 (2002).
124. Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434-2439 (2001).
125. Abu-Duhier FM, Goodeve AC, Wilson GA et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113, 983-988 (2001).
126. Frohling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100, 4372-4380 (2002).
127. Grundler R, Thiede C, Miething C et al. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 102, 646-651 (2003).
128. Armstrong SA, Kung AL, Mabon ME et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183 (2003).
129. Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1, 433-443 (2002).
130. Ganeshaguru K, Wickremasinghe RG, Jones DT et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 87, 167-176 (2002).
131. Miknyoczki SJ, Chang H, Klein-Szanto A et al. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 5, 2205-2212 (1999).
132. Tatton L, Morley GM, Chopra R et al. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. 278, 4847-4853 (2003).
133. Svingen PA, Tefferi A, Kottke TJ et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin. Cancer Res. 6, 237-249 (2000).
134. Sun X, Layton JE, Elefanty A et al. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490 and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 97, 2008-2015 (2001).
135. Mow BM, Chandra J, Svingen PA et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99, 664-671 (2002).
136. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807-826 (2001).
137. Sabatini DM, Erdjument-Bromage H, Lui M et al. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43 (1994).
138. Sabers CJ, Martin MM, Brunn GJ et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815-822 (1995).
139. Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758 (1994).
140. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl Acad. Sci. USA 91, 12574-12578 (1994).
141. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726 (1975).
142. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727-732 (1975).
143. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31, 335-340 (1998).
144. Houchens DP, Ovejera AA, Riblet SM et al. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol. 19, 799-805 (1983).
145. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8, 63-87 (1981).
146. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. (Tokyo) 37, 1231-1237 (1984).
147. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nature Rev. Mol. Cell Biol. 4, 117-126 (2003).
148. Sarkaria JN, Tibbetts RS, Busby EC et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58, 4375-4382 (1998).
149. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol. Ther. 2, 222-232 (2003).
150. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262-267 (1998).
151. Pause A, Belsham GJ, Gingras AC et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371, 762-767 (1994).
152. Mendez R, Myers MG Jr, White MF et al. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell Biol. 16, 2857-2864 (1996).
153. Rosenwald IB, Kaspar R, Rousseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 270, 21176-21180 (1995).
154. Rousseau D, Kaspar R, Rosenwald I et al. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl Acad. Sci. USA 93, 1065-1070 (1996).
155. Hashemolhosseini S, Nagamine Y, Morley SJ et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273, 14424-14429 (1998).
156. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 54, 2313-2316 (1994).
157. Hu Q, Klippel A, Muslin AJ et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268, 100-102 (1995).
158. Park IH, Bachmann R, Shirazi H et al. Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J. Biol. Chem. 277, 31423-31429 (2002).
159. Mayerhofer M, Valent P, Sperr WR et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100, 3767-3775 (2002).
160. Alexandre J, Raymond E, Armand JP. [Rapamycin and CCI-779]. Bull. Cancer 86, 808-811 (1999).
161. Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16, 1101-1114 (2002).
162. Dudkin L, Dilling MB, Cheshire PJ et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758-1764 (2001).
163. Geoerger B, Kerr K, Tang CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61, 1527-1532 (2001).
164. Grunwald V, DeGraffenried L, Russel D et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62, 6141-6145 (2002).
165. Harding MW. Immunophilins, mTOR and pharmacodynamic strategies for a targeted cancer therapy. Commentary re: JM Peralba et al., Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9, 2887-2892 (2003). Clin. Cancer Res. 9, 2882-2886 (2003).
166. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686 (2000).
167. Hu L, Shi Y, Hsu JH et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101, 3126-3135 (2003).
168. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr. Opin. Investig. Drugs 3, 295-304 (2002).
169. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3, 371-377 (2003).
170. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 4, 126-137 (2003).
171. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
172. Peralba JM, DeGraffenried I, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9, 2887-2892 (2003).
173. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8, 249-258 (2001).
174. McMahon LM, Luo S, Hayes M et al. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system. Rapid Commun. Mass Spectrom. 14, 1965-1971 (2000).
175. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75, 1710-1717 (2003).
176. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B-lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of post-transplant lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 97, 4285-4290 (2000).
177. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349, 847-858 (2003).